Some studies suggest combining GLP-1 therapy with metformin may provide additive benefits
[Abstract] Cell viability was measured after being pretreated with Fer-1 (2 M), GSH (1 mM), or DFO (50 M) for 1 h, and then treated with or without Sal (50 M) for 24 h (n = 6)
In addition to these widely used AOMs, Exenatide, one of the earliest GLP-1 RAs approved by the FDA and EMA for T2DM management, is not indicated for weight management but remains clinically relevant, particularly in older adults with comorbid obesity and T2DM, given its long-term clinical experience and established tolerability profile [26,27,28]
Another company, MetroBiotech (which falls under the holding company EdenRoc Sciences), is pursuing drugs inspired by the NAD+ booster NMN
GLP-1s affect appetite, muscle mass, energy, and multiple metabolic systems over time